Home  |  Archive  |  AJA @ Nature  |  Online Submission  |  News & Events  |  Subscribe  |  APFA  |  Society  |  Links  |  Contact Us  |  中文版
Journal

- Advance Online Publication
- Current Issue
- Free Sample Issue
- Browse by Volume
- Browse by Category
- Acknowledgments
- Special Issues
- AJA @ NPG

Manuscript Submission

- Online Submission
- Online Review
- Instruction for Authors
- Instruction for Reviewers
- English Corner new!

About AJA

- About AJA
- Editorial Board
- Contact Us
- News

About NPG

- Nature.com
- Nature Publishing Group

Resources & Services

- Advertisement
- Subscription
- Email alert
- Proceedings
- Reprints

Download area

- Copyright Licence
- Subscription
- Free Sample

Links

- Journals
- Societies & Institutes
- Hospitals
- Databases & Libraries
- Companies
- Websites
- Meetings
- Other links

 
Abstract

Asian Journal of Andrology (2013) 15, 138–142; doi:10.1038/aja.2012.96; published online 29 October 2012

Safety and efficacy of tramadol hydrochloride on treatment of premature ejaculation

Bayoumy I Eassa1 and Mohamed A El-Shazly2

1 Department of Dermatology, Venereology and Andrology, Al-Azhar University, Cairo 11884, Egypt
2 Department of Urology, Menoufiya University, Cairo 32511, Egypt

Correspondence: Dr BI Eassa, (bayeassa@yahoo.com)

Received 15 April 2012; Revised 17 May 2012; Accepted 25 July 2012
Advance online publication 29 October 2012

Abstract
Premature ejaculation (PE) is the most common sexual disorder. It affects 20%–30% of adult men; the aetiology of this condition has not yet been elucidated. The aim of this study is to evaluate the efficacy, safety, tolerability, undesirable effects and improved satisfaction with sexual intercourse with tramadol hydrochloride at different dosages for the treatment of PE. A total of 300 patients who presented with lifelong (primary) PE were included in this study. The study was performed for 28 weeks, in which placebo (starch tablet) was given for 4 weeks, and active ingredient (tramadol hydrochloride) was administered at different therapeutic dosages for 24 weeks. Patients were divided into three equal groups, each consisting of 100 patients. The first group (A) was given tramadol hydrochloride capsule 25 mg. The second group (B) was given tramadol hydrochloride capsule 50 mg. The third group (C) was given tramadol hydrochloride capsule 100 mg. All of the 300 participants included completed the study voluntarily. The age of the patients varied from 25 to 50 years. After the treatment period, the recorded data were collected for each group and analysed. The results showed a highly significant increase in the mean intravaginal ejaculatory latency time (IELT) in all groups compared to baseline data (P<0.0001). We concluded that using tramadol hydrochloride at different doses on demand for the treatment of PE is effective, safe and tolerable, with minimal undesirable effects, and approval for this indication should be sought.

Keywords: early ejaculation; erectile dysfunction; intravaginal ejaculation latency time; premature climax; premature ejaculation; PE; rapid ejaculation; tramadol

 

Copyright 1999-2013    Shanghai Materia Medica, Shanghai Jiao Tong University.    All rights reserved